1) Dürst M, Gissmann L, Ikenberg H, et al : A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80:3812-3815,1983
2) Zhou J, Sun XY, Stenzel DJ, et al : Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251-257,1991
3) Stanley M : Prophylactic HPV vaccines. J Clin Pathol 60:961-965,2007
4) Dillner J, Kjaer SK, Wheeler CM, et al : Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts : randomised controlled trial. BMJ 341:c3493,2010
5) Wheeler CM, Hunt WC, Joste NE, et al : Human papillomavirus genotype distributions : implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 101:475-487,2009
6) Brotherton JM, Fridman M, May CL, et al : Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia : an ecological study. Lancet 377:2085-2092,2011
7) Donovan B, Franklin N, Guy R, et al : Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia : analysis of national sentinel surveillance data. Lancet Infect Dis 11:39-44,2011
8) Colgrove J : The ethics and politics of compulsory HPV vaccination. N Engl J Med 355:2389-2391,2006
9) Inoue M, Sakaguchi J, Sasagawa T, et al : The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer 16:1007-1013,2006
10) Onuki M, Matsumoto K, Satoh T, et al : Human papillomavirus infections among Japanese women : age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 100:1312-1316,2009